A hepatitis C-vírus (HCV) három évtizede a felfedezéstől a globális elimináció lehetőségéig: A transzlációs kutatás sikere

Research output: Review article

2 Citations (Scopus)

Abstract

More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90% efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants. In addition, the lack of vaccine is also an obstacle. In 2016, the World Health Organization (WHO) developed the first global health sector strategy for the elimination of viral hepatitis by 2030. Its evidence-based guidelines are primarily targeted at the national hepatitis programme managers who are responsible for the national testing and treatment plans. According to these recommendations, it is of basic importance to perform focused risk-based testing in higher-risk populations and after diagnosis to start treatment as “cure as prevention”, furthermore, to limit the risk of reinfection. We review the events of the HCV story from the discovery to these days, including virology, epidemiology, pathogenesis, diagnosis and therapy.

Original languageHungarian
Pages (from-to)455-465
Number of pages11
JournalOrvosi Hetilap
Volume159
Issue number12
DOIs
Publication statusPublished - márc. 1 2018

Fingerprint

Translational Medical Research
Hepacivirus
Hepatitis
Therapeutics
Virology
Drug Resistance
Antiviral Agents
Epidemiology
Vaccines
Guidelines
Viruses
Population

Keywords

  • Diagnosis
  • Elimination
  • Epidemiology
  • Hepatitis C virus
  • Pathogenesis
  • Prevention
  • Screening
  • Treatment
  • Virology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{3b024614c3fa426c8de53c4a99a04250,
title = "A hepatitis C-v{\'i}rus (HCV) h{\'a}rom {\'e}vtizede a felfedez{\'e}stől a glob{\'a}lis elimin{\'a}ci{\'o} lehetős{\'e}g{\'e}ig: A transzl{\'a}ci{\'o}s kutat{\'a}s sikere",
abstract = "More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90{\%} efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants. In addition, the lack of vaccine is also an obstacle. In 2016, the World Health Organization (WHO) developed the first global health sector strategy for the elimination of viral hepatitis by 2030. Its evidence-based guidelines are primarily targeted at the national hepatitis programme managers who are responsible for the national testing and treatment plans. According to these recommendations, it is of basic importance to perform focused risk-based testing in higher-risk populations and after diagnosis to start treatment as “cure as prevention”, furthermore, to limit the risk of reinfection. We review the events of the HCV story from the discovery to these days, including virology, epidemiology, pathogenesis, diagnosis and therapy.",
keywords = "Diagnosis, Elimination, Epidemiology, Hepatitis C virus, Pathogenesis, Prevention, Screening, Treatment, Virology",
author = "A. P{\'a}r and G. P{\'a}r",
year = "2018",
month = "3",
day = "1",
doi = "10.1556/650.2018.30997",
language = "Hungarian",
volume = "159",
pages = "455--465",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "12",

}

TY - JOUR

T1 - A hepatitis C-vírus (HCV) három évtizede a felfedezéstől a globális elimináció lehetőségéig

T2 - A transzlációs kutatás sikere

AU - Pár, A.

AU - Pár, G.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90% efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants. In addition, the lack of vaccine is also an obstacle. In 2016, the World Health Organization (WHO) developed the first global health sector strategy for the elimination of viral hepatitis by 2030. Its evidence-based guidelines are primarily targeted at the national hepatitis programme managers who are responsible for the national testing and treatment plans. According to these recommendations, it is of basic importance to perform focused risk-based testing in higher-risk populations and after diagnosis to start treatment as “cure as prevention”, furthermore, to limit the risk of reinfection. We review the events of the HCV story from the discovery to these days, including virology, epidemiology, pathogenesis, diagnosis and therapy.

AB - More than 25 years after the discovery of hepatitis C virus, the development of the direct acting antivirals can lead to the regional or long-term global elimination of the virus with over 90% efficacy. This is the success of basic and clinical translational research. Yet, some unsolved challanges remain, such as the great number of unidentified patients who are not aware of their condition, the limited access to the therapy due to the high prices of the drugs, and the treatment of resistance-associated variants. In addition, the lack of vaccine is also an obstacle. In 2016, the World Health Organization (WHO) developed the first global health sector strategy for the elimination of viral hepatitis by 2030. Its evidence-based guidelines are primarily targeted at the national hepatitis programme managers who are responsible for the national testing and treatment plans. According to these recommendations, it is of basic importance to perform focused risk-based testing in higher-risk populations and after diagnosis to start treatment as “cure as prevention”, furthermore, to limit the risk of reinfection. We review the events of the HCV story from the discovery to these days, including virology, epidemiology, pathogenesis, diagnosis and therapy.

KW - Diagnosis

KW - Elimination

KW - Epidemiology

KW - Hepatitis C virus

KW - Pathogenesis

KW - Prevention

KW - Screening

KW - Treatment

KW - Virology

UR - http://www.scopus.com/inward/record.url?scp=85044160440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044160440&partnerID=8YFLogxK

U2 - 10.1556/650.2018.30997

DO - 10.1556/650.2018.30997

M3 - Review article

C2 - 29552922

AN - SCOPUS:85044160440

VL - 159

SP - 455

EP - 465

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 12

ER -